Quantitative metabolomics identifies prognostic biomarkers in non-small cell lung cancer, indicating the potential for precision therapy.
Introduction: The high mortality of non-small cell lung cancer (NSCLC) is influenced by pre-treatment individual variability, yet reliable prognostic biomarkers are lacking, hindering precision therapy.Objectives: This study aimed to identify...
No takes yet. Share an insight, caveat, or question.
Leirui et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: